Bionano Genomics, Inc. (BNGO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BNGO SEC filings page.
Bionano Genomics, Inc. (BNGO) reported $30.2M in revenue over the twelve months to Jun 30, 2026, up 10.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
2025’s lower sales produced much better margins, but the business still consumed cash and remained unprofitable.
The unusual pattern is margin expansion without sales growth: revenue fell from$30.8M to$28.5M even as gross margin rose sharply. That reversal points to lower production costs or a changed revenue mix rather than scale alone; cash conversion also improved with earnings, indicating less cash consumption as the reported deficit narrowed.
Operating expense reduction was a major part of the improvement: core operating expenses fell from
Operating cash flow improved from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bionano Genomics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bionano Genomics, Inc. held $19.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $16.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Bionano Genomics, Inc. scores 37/100 among other emerging companies.
Bionano Genomics, Inc. had 11M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Bionano Genomics, Inc. scores 89/100 among other emerging companies.
Bionano Genomics, Inc. spent $11.4M on research and development in fiscal year 2025, which was 18.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Bionano Genomics, Inc. scores 49/100 among other emerging companies.
Bionano Genomics, Inc. reported revenue of $28.5M in fiscal year 2025, against $30.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Bionano Genomics, Inc. scores 29/100 among other emerging companies.
Bionano Genomics, Inc.'s operations used $16.3M of cash in fiscal year 2025, against $68.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Bionano Genomics, Inc. scores 84/100 among other emerging companies.
Bionano Genomics, Inc.'s cash, cash equivalents and investments came to $19.3M at the end of fiscal year 2025, against $29.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Bionano Genomics, Inc. scores 49/100 among other emerging companies.
Bionano Genomics, Inc. scores -14.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($17.2M) relative to total liabilities ($29.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bionano Genomics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Bionano Genomics, Inc. reported a net loss of $26.4M while operations used $16.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bionano Genomics, Inc. generated $8.2M in revenue in Q2 2026. This represents an increase of 21.4% from the same quarter a year earlier. Against the prior quarter it is up 22.2%.
Bionano Genomics, Inc.'s EBITDA was -$6.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.6% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.
Bionano Genomics, Inc. reported -$7.4M in net income in Q2 2026. This represents a decrease of 8.3% from the same quarter a year earlier. Against the prior quarter it is up 10.6%.
Bionano Genomics, Inc. earned -$0.64 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 15.8%.
Cash & Balance Sheet
Bionano Genomics, Inc. held $3.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Bionano Genomics, Inc.'s gross margin was 52.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.
Bionano Genomics, Inc.'s operating margin was -88.3% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Bionano Genomics, Inc.'s net profit margin was -90.8% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Bionano Genomics, Inc.'s ROE was -23.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.
Capital Allocation
Bionano Genomics, Inc. invested $3.0M in research and development in Q2 2026. This represents an increase of 1.9% from the same quarter a year earlier. Against the prior quarter it is down 4.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BNGO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M+21.4% | $6.7M+3.6% | $8.0M-2.6% | $7.4M+21.3% | $6.7M-13.4% | $6.5M-26.4% | $8.2M-23.9% | $6.1M-34.8% |
| Cost of Revenue | $3.9M+18.5% | $3.4M-2.4% | $4.6M-4.1% | $4.0M-72.5% | $3.3M-37.2% | $3.5M-40.8% | $4.7M-42.7% | $14.5M+121.0% |
| Gross Profit | $4.3M+24.1% | $3.3M+10.7% | $3.4M-0.5% | $3.4M+139.9% | $3.5M+34.5% | $2.9M+4.0% | $3.4M+40.1% | -$8.4M-407.2% |
| R&D Expenses | $3.0M+1.9% | $3.1M+32.4% | $3.2M-7.1% | $2.8M-39.7% | $2.9M-57.1% | $2.4M-75.8% | $3.5M-70.3% | $4.7M-65.8% |
| SG&A Expenses | $8.5M+2.4% | $8.0M-11.3% | $8.7M-25.9% | $9.1M-4.2% | $8.3M-27.8% | $9.0M-52.7% | $11.7M-21.4% | $9.5M-62.0% |
| Operating Income | -$7.2M+7.5% | -$7.9M+6.7% | -$8.5M+28.5% | -$8.5M+80.6% | -$7.8M+54.2% | -$8.5M+72.8% | -$11.9M+52.1% | -$43.9M+61.2% |
| EBITDA | -$6.2M+8.6% | -$5.6M+7.4% | -$4.9M+49.0% | -$6.2M+83.9% | -$6.7M+51.9% | -$6.0M+78.5% | -$9.5M+55.3% | -$38.3M+65.1% |
| Income Tax | $7K-30.0% | $10K+42.9% | $36K+3500.0% | $14K-41.7% | $10K-61.5% | $7K+138.9% | $1K+102.8% | $24K-38.5% |
| Net Income | -$7.4M-8.3% | -$8.3M-167.7% | -$7.9M+60.6% | -$8.5M+80.8% | -$6.9M+57.7% | -$3.1M+90.1% | -$20.1M+54.1% | -$44.2M+60.7% |
| EPS (Basic) | -$0.64+67.8% | -$0.76+33.9% | -$0.03+99.6% | -$1.59+94.9% | -$1.99+86.2% | -$1.15+96.8% | -$7.95-728.1% | -$30.92-860.2% |
| EPS (Diluted) | -$0.64 | -$0.76 | -$0.03 | -$1.59 | -$1.99 | -$1.15 | -$7.95 | -$30.92 |
| Diluted Shares (Avg) | 12M | 11M | N/A | 5M | 3M | 3M | N/A | 1M |
Not reported in any period shown, so not listed: Interest Expense.
BNGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $47.6M-37.4% | $64.8M-17.4% | $73.6M-4.0% | $79.1M-9.5% | $76.0M-41.2% | $78.4M-50.4% | $76.7M-64.2% | $87.4M-52.0% |
| Current Assets | $24.9M-41.7% | $39.0M-13.3% | $45.4M+14.9% | $48.8M+3.9% | $42.7M-29.6% | $44.9M-47.5% | $39.5M-71.8% | $47.0M-55.1% |
| Cash & Equivalents | $3.7M+4.7% | $3.4M-5.5% | $3.0M-67.4% | $3.1M-65.1% | $3.6M-65.8% | $3.6M-77.0% | $9.2M-48.9% | $8.8M-74.6% |
| Short-Term Investments | $6.2M-51.9% | $11.0M-24.8% | $16.3M+5290.4% | $18.5M+485.9% | $12.9M+51.2% | $14.6M+16.3% | $302K-99.4% | $3.2M-89.1% |
| Inventory | $7.0M-31.9% | $7.7M-32.7% | $7.8M-41.0% | $8.4M-48.3% | $10.3M-55.5% | $11.4M-52.0% | $13.3M-51.9% | $16.3M-51.4% |
| Accounts Receivable | $4.4M+25.0% | $4.1M+23.2% | $5.2M+9.4% | $4.5M-14.9% | $3.5M-44.2% | $3.4M-59.7% | $4.8M-49.0% | $5.3M-38.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $16.0M-47.8% | $27.3M-9.5% | $29.2M-29.4% | $29.3M-24.0% | $30.6M-37.5% | $30.2M-59.8% | $41.3M-65.1% | $38.5M-38.8% |
| Current Liabilities | $10.0M-58.5% | $21.2M-19.6% | $22.9M-38.6% | $23.0M-30.3% | $24.2M-35.0% | $26.4M-54.9% | $37.3M-62.7% | $33.0M-18.0% |
| Non-Current Liabilities | $5.9M-7.9% | $6.1M+60.1% | $6.2M+57.4% | $6.3M+13.4% | $6.5M-45.5% | $3.8M-77.2% | $4.0M-78.3% | $5.5M-75.6% |
| Total Equity | $31.6M-30.3% | $37.5M-22.3% | $44.4M+25.6% | $49.8M+1.9% | $45.4M-43.5% | $48.2M-41.8% | $35.4M-63.2% | $48.9M-58.9% |
| Retained Earnings | -$735.3M-4.6% | -$727.9M-4.5% | -$719.6M-3.8% | -$711.7M-5.7% | -$703.2M-11.8% | -$696.3M-13.7% | -$693.2M-19.3% | -$673.1M-25.3% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BNGO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.7M-33.9% | -$5.7M-106.8% | -$4.2M+35.8% | -$5.9M+55.5% | -$3.5M+83.4% | -$2.8M+90.2% | -$6.5M+78.2% | -$13.3M+49.4% |
| Depreciation & Amortization | $1.1M0.0% | $2.3M-5.1% | $2.3M-2.5% | $2.4M-57.8% | $1.1M-64.8% | $2.4M-19.1% | $2.4M-33.3% | $5.6M+55.3% |
| Stock-Based Compensation | $970K-10.2% | $670K-57.8% | N/A | $941K-57.3% | $1.1M-58.2% | $1.6M-47.4% | N/A | $2.2M-44.8% |
| Investing Cash Flow | $13.7M+591.3% | $5.5M+138.8% | $4.0M+33.8% | -$4.7M+13.1% | $2.0M-93.1% | -$14.1M-129.6% | $3.0M+105.4% | -$5.4M-116.1% |
| Financing Cash Flow | -$9.7M-759.8% | $657K-94.0% | $1.6M-58.8% | $10.1M+67.3% | $1.5M+174.3% | $10.9M+150.4% | $3.9M-94.3% | $6.0M-52.2% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BNGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8%+1.2pp | 48.6%+3.1pp | 42.8%+0.9pp | 45.7% | 51.6%+18.4pp | 45.5%+13.3pp | 41.9%+19.1pp | -139.1% |
| Operating Margin | -88.3% | -118.1% | -107.4% | -115.9% | -115.9% | -131.1% | -146.3% | -722.9% |
| Net Margin | -90.8% | -124.2% | -99.8% | -115.4% | -101.8% | -48.0% | -246.5% | -728.6% |
| Return on Equity | -23.5%-8.4pp | -22.2%-15.7pp | -17.9%+39.0pp | -17.1%+73.5pp | -15.1%+5.1pp | -6.4%+31.5pp | -56.9%-11.2pp | -90.5%+4.0pp |
| Return on Assets | -15.6%-6.6pp | -12.8%-8.8pp | -10.8%+15.5pp | -10.8%+39.9pp | -9.0%+3.5pp | -4.0%+15.9pp | -26.3%-5.8pp | -50.6%+11.2pp |
| Current Ratio | 2.48+0.7x | 1.84+0.1x | 1.98+0.9x | 2.12+0.7x | 1.76+0.1x | 1.70+0.2x | 1.06-0.3x | 1.43-1.2x |
| Debt-to-Equity | 0.51-0.2x | 0.73+0.1x | 0.66-0.5x | 0.59-0.2x | 0.68+0.1x | 0.63-0.3x | 1.17-0.1x | 0.79+0.3x |
| Asset Turnover | 0.17+0.1x | 0.100.0x | 0.110.0x | 0.090.0x | 0.090.0x | 0.080.0x | 0.11+0.1x | 0.070.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bionano Genomics, Inc. BNGO | FY2025 | $28.5M | -$26.4M | -92.6% | $17.2M | 56/100 |
| Harvard Bioscience Inc HBIO | FY2025 | $86.5M | -$56.7M | -65.5% | $38.7M | 38/100 |
| NexGel, Inc NXGL | FY2025 | $11.4M | -$3.0M | -26.3% | $1.7M | 37/100 |
| Retractable Technologies, Inc RVP | FY2025 | $38.3M | -$12.6M | -32.8% | $20.7M | 24/100 |
| Meihua International Medical Technologies Co., Ltd. MHUA | FY2025 | $61.8M | $6.8M | 11.0% | $425.4M | 59/100 |
| Femasys Inc. FEMY | FY2025 | $2.3M | -$18.6M | N/A | $16.8M | 43/100 |
Where Bionano Genomics, Inc. Ranks
Frequently Asked Questions
What is Bionano Genomics, Inc.'s annual revenue?
Bionano Genomics, Inc. (BNGO) reported $28.5M in total revenue for fiscal year 2025. This represents a -7.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bionano Genomics, Inc.'s revenue growing?
Bionano Genomics, Inc. (BNGO) revenue declined by 7.4% year-over-year, from $30.8M to $28.5M in fiscal year 2025.
Is Bionano Genomics, Inc. profitable?
No, Bionano Genomics, Inc. (BNGO) reported a net income of -$26.4M in fiscal year 2025, with a net profit margin of -92.6%.
What is Bionano Genomics, Inc.'s EBITDA?
Bionano Genomics, Inc. (BNGO) had EBITDA of -$23.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bionano Genomics, Inc.'s gross margin?
Bionano Genomics, Inc. (BNGO) had a gross margin of 46.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bionano Genomics, Inc.'s net profit margin?
Bionano Genomics, Inc. (BNGO) had a net profit margin of -92.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bionano Genomics, Inc.'s return on equity (ROE)?
Bionano Genomics, Inc. (BNGO) has a return on equity of -59.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bionano Genomics, Inc.'s operating cash flow?
Bionano Genomics, Inc. (BNGO) recorded an outflow of $16.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bionano Genomics, Inc.'s total assets?
Bionano Genomics, Inc. (BNGO) had $73.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bionano Genomics, Inc. spend on research and development?
Bionano Genomics, Inc. (BNGO) invested $11.4M in research and development during fiscal year 2025.
What is Bionano Genomics, Inc.'s current ratio?
Bionano Genomics, Inc. (BNGO) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.
What is Bionano Genomics, Inc.'s debt-to-equity ratio?
Bionano Genomics, Inc. (BNGO) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bionano Genomics, Inc.'s return on assets (ROA)?
Bionano Genomics, Inc. (BNGO) had a return on assets of -35.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bionano Genomics, Inc.'s P/E ratio?
Bionano Genomics, Inc. (BNGO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $17.2M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bionano Genomics, Inc.'s price-to-sales ratio?
Bionano Genomics, Inc. (BNGO) trades at 0.6x sales, its market capitalization divided by revenue of $30.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $17.2M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Bionano Genomics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Bionano Genomics, Inc. (BNGO) held $19.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.3M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Bionano Genomics, Inc.'s Altman Z-Score?
Bionano Genomics, Inc. (BNGO) has an Altman Z-Score of -14.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bionano Genomics, Inc.'s Piotroski F-Score?
Bionano Genomics, Inc. (BNGO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bionano Genomics, Inc.'s earnings high quality?
Bionano Genomics, Inc. (BNGO) reported a net loss of $26.4M while operations used $16.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bionano Genomics, Inc.?
Bionano Genomics, Inc. (BNGO) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.